GLP-1 Pricing ‘Paradigm Shift’ Possible, But Would It Meet Trump’s MFN Goals?

 
• By Cathy Kelly
  
Lilly and Novo could follow the same path as insulins. (Shutterstock)

More from Pricing Debate

More from Geography